Luxna Biotech Co., Ltd. announced that it has entered into an option agreement with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France) to grant an exclusive license to use Luxna’s breakthrough xeno nucleic acid technology in the field of neurological diseases.

Please check here for details.